FDA clears hands-free robotic system for CT exams

XACT Robotics, a radiology technology company with offices in Hingham, Massachusetts, and Israel, received FDA clearance for the use of its hands-free robotic system during CT examinations.

This is the first hands-free robotic solution of its kind, according to the company, providing users with both imaging-based navigation and the ability to insert and steer “various instruments to a desired target across an array of clinical applications and indications.”

“We are committed to redefining the way the entire medical community utilizes robotics, beginning with interventional radiologists,” Harel Gadot, founder, executive chairman and president of XACT Robotics, said in a prepared statement. “Being the first to introduce a hands-free robotic system, we have the potential to provide significant clinical, technical and economic value while democratizing interventional procedures. Our system’s small footprint and high mobility design will enable care providers to treat a broad range of patient care needs in various clinical sites of service.”  

“The XACT Robotic System provides a unique platform to the interventional radiology community which can help improve the delivery and quality of care for the patients we serve,” Nahum S. Goldberg, MD, director of the Applied Radiology Research Lab at Hadassah Hebrew University Medical Center in Israel, said in the same statement. “Based on our experience with this unique robotic technology, we can reach very small targets with unprecedented accuracy. Furthermore, this system holds much promise for enabling more efficient use of time and hospital resources.”

Goldberg has spent significant time with the solution, even leading a multi-site study into its effectiveness.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.